Fighting Cancer With Killer T-Cells: 5 Developments To Watch
Three companies are locked in a tight race to develop next-generation immuno-oncology treatments called chimeric antigen receptor T-cells (CARTs)—sophisticated, personalized medicines that use patients’ own cells to destroy their tumors: Juno Therapeutics, Novartis and Kite Pharma.
So all eyes were on those companies at the annual meeting of the American Association for Cancer Research (AACR), which wrapped up yesterday in New Orleans.
So all eyes were on those companies at the annual meeting of the American Association for Cancer Research (AACR), which wrapped up yesterday in New Orleans.